{"title":"关于GLP-1受体激动剂你需要知道什么?","authors":"K. Carmichael","doi":"10.25270/con.2022.02.00004","DOIUrl":null,"url":null,"abstract":"Glucagon-like peptide 1 (GLP-1) agonists are an important class of medications for patients with type 2 diabetes and should be considered for long-term therapy. A study of noninsulin treatment of type 2 diabetes in the United States showed that there has been a gradual decline in metformin use (from 57.0% in 2015 to 46.0% in 2019), an increase of GLP-1 agonist monotherapy use (from 4.3% in 2015 to 8.5% in 2019), and an increase in overall combined therapy use (from 9.8% in 2015 to 18.2% in 2019).1 Adequate management of diabetes with safe glycemic control is essential for reducing progression of chronic kidney disease, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD).","PeriodicalId":35575,"journal":{"name":"Consultant","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"What Do You Need to Know About GLP-1 Receptor Agonists?\",\"authors\":\"K. Carmichael\",\"doi\":\"10.25270/con.2022.02.00004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Glucagon-like peptide 1 (GLP-1) agonists are an important class of medications for patients with type 2 diabetes and should be considered for long-term therapy. A study of noninsulin treatment of type 2 diabetes in the United States showed that there has been a gradual decline in metformin use (from 57.0% in 2015 to 46.0% in 2019), an increase of GLP-1 agonist monotherapy use (from 4.3% in 2015 to 8.5% in 2019), and an increase in overall combined therapy use (from 9.8% in 2015 to 18.2% in 2019).1 Adequate management of diabetes with safe glycemic control is essential for reducing progression of chronic kidney disease, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD).\",\"PeriodicalId\":35575,\"journal\":{\"name\":\"Consultant\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Consultant\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25270/con.2022.02.00004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Consultant","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25270/con.2022.02.00004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
What Do You Need to Know About GLP-1 Receptor Agonists?
Glucagon-like peptide 1 (GLP-1) agonists are an important class of medications for patients with type 2 diabetes and should be considered for long-term therapy. A study of noninsulin treatment of type 2 diabetes in the United States showed that there has been a gradual decline in metformin use (from 57.0% in 2015 to 46.0% in 2019), an increase of GLP-1 agonist monotherapy use (from 4.3% in 2015 to 8.5% in 2019), and an increase in overall combined therapy use (from 9.8% in 2015 to 18.2% in 2019).1 Adequate management of diabetes with safe glycemic control is essential for reducing progression of chronic kidney disease, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
